Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -423 Thousand SEK | -4.19% |
| 2022 | -406 Thousand SEK | -4.64% |
| 2021 | -388 Thousand SEK | -335.96% |
| 2020 | -89 Thousand SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | 100.0% |
| 2017 | -31 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q4 | - SEK | 0.0% |
| 2023 FY | -423 Thousand SEK | -4.19% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2022 Q3 | - SEK | 100.0% |
| 2022 Q1 | -100 Thousand SEK | -3.09% |
| 2022 FY | -406 Thousand SEK | -4.64% |
| 2022 Q4 | - SEK | 0.0% |
| 2022 Q2 | -100 Thousand SEK | 0.0% |
| 2021 Q2 | -97 Thousand SEK | 0.0% |
| 2021 Q3 | -97 Thousand SEK | 0.0% |
| 2021 Q4 | -97 Thousand SEK | 0.0% |
| 2021 FY | -388 Thousand SEK | -335.96% |
| 2021 Q1 | -97 Thousand SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | -89 Thousand SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | - SEK | 100.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | -31 Thousand SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 99.737% |
| Ziccum AB (publ) | -23.28 Million SEK | 98.183% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.122% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 101.012% |
| Mendus AB (publ) | 28.48 Million SEK | 101.485% |
| Genovis AB (publ.) | 54 Million SEK | 100.783% |
| Intervacc AB (publ) | -13.79 Million SEK | 96.933% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 119.484% |
| Active Biotech AB (publ) | -1.67 Million SEK | 74.746% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 104.246% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 101.577% |
| Aptahem AB (publ) | 2.63 Million SEK | 116.08% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 87.635% |
| Kancera AB (publ) | -1.96 Million SEK | 78.473% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 649.351% |
| Fluicell AB (publ) | 1.73 Million SEK | 124.338% |
| Saniona AB (publ) | 11.78 Million SEK | 103.591% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 91.733% |
| Biovica International AB (publ) | 6.87 Million SEK | 106.151% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 98.183% |
| AcouSort AB (publ) | 8.38 Million SEK | 105.042% |
| Xintela AB (publ) | 78 Thousand SEK | 642.308% |
| Abliva AB (publ) | -35.66 Million SEK | 98.814% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 99.712% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 115.069% |
| OncoZenge AB (publ) | 3000.00 SEK | 14200.0% |
| Amniotics AB (publ) | -1.93 Million SEK | 78.083% |
| 2cureX AB (publ) | -37.48 Million SEK | 98.872% |
| CombiGene AB (publ) | -21.29 Million SEK | 98.013% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.037% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.027% |
| Corline Biomedical AB | 28.38 Million SEK | 101.49% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 99.655% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 98.771% |
| I-Tech AB | 27.56 Million SEK | 101.534% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 100.596% |
| Cyxone AB (publ) | 2.61 Million SEK | 116.201% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 112.43% |
| Biosergen AB | -456 Thousand SEK | 7.237% |
| Cantargia AB (publ) | -3.45 Million SEK | 87.743% |
| NextCell Pharma AB | -43.74 Million SEK | 99.033% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 95.399% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 103.771% |
| Nanologica AB (publ) | -76 Thousand SEK | -456.579% |
| SynAct Pharma AB | -778 Thousand SEK | 45.63% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -119.171% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 96.727% |
| Lipum AB (publ) | 53 Thousand SEK | 898.113% |
| BioInvent International AB (publ) | 71.46 Million SEK | 100.592% |
| Alzinova AB (publ) | 19.87 Million SEK | 102.128% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 101.165% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 128.913% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -2720.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 125.513% |
| Simris Alg AB (publ) | 2 Million SEK | 121.076% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 88.184% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 101.195% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 59.676% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 113.501% |